The expression of MYCN was increased gradually with tumor stage development and upregulated in poor or undifferentiated tumors compared with normal tissues (Fig. 7i–k), which was significantly associated with poor clinical outcome (Fig. 7l). Here, MYCN is linked to neoplasm.